PRF Technologies Announces PRF-110 Demonstrated Sustained 72-Hour Analgesic Activity Comparable to Approved, Commercially Available Benchmark in Head-to-Head Preclinical Study

Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable safety profile